

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE  
HIGHLY SPECIALISED TECHNOLOGY EVALUATION PROGRAMME**

**Equality impact assessment – Scoping**

**Eliglustat for treating type 1 Gaucher disease**

**Batch 34**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No potential equality issues were identified during the scoping process.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

No potential equality issues were identified that would need to be addressed by the Committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the scope were required.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders related to potential equality issues were identified.

**Approved by Associate Director (name):** Sheela Upadhyaya .....  
**Date:** 09/02/2016